Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment

Pexa-Vec (pexastimogene devacirpvec; JX-594) has emerged as an attractive tool in oncolytic virotherapy. Pexa-Vec demonstrates oncolytic and immunotherapeutic mechanisms of action. But the determinants of resistance to Pexa-Vec are mostly unknown. We treated hemoatologic malignant cells with Pexa-Ve...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Nam Hee, Kim, Mikyung, Oh, Sung Yong, Kim, Seong-Geun, Kwon, Hyuk-Chan, Hwang, Tae-Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352049/
https://www.ncbi.nlm.nih.gov/pubmed/27901484
http://dx.doi.org/10.18632/oncotarget.13598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352049/
https://www.ncbi.nlm.nih.gov/pubmed/27901484
http://dx.doi.org/10.18632/oncotarget.13598

Ejemplares similares